Li-hua Hou
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV.
Journal: Emerging microbes & infections
Published: August 23, 2024
Molecular basis of Ad5-nCoV vaccine-induced immunogenicity.
Journal: Structure (London, England : 1993)
Published: July 18, 2024
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Journal: Emerging microbes & infections
Published: November 07, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Journal: The Lancet regional health. Western Pacific
Published: April 12, 2023
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: April 04, 2023
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above.
Journal: Expert review of vaccines
Published: September 01, 2022
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
Journal: The Lancet. Respiratory medicine
Published: January 05, 2022
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: June 15, 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Journal: Lancet (London, England)
Published: May 08, 2020
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Journal: The Lancet. Global health
Published: October 19, 2016
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: September 20, 2016
Comparative study on fermentation performance in the genome shuffled Candida versatilis and wild-type salt tolerant yeast strain.
Journal: Journal of the science of food and agriculture
Published: July 23, 2015
Last Updated: 09/26/2026